Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation Jones KB; Haldar M; Schiffman JD; Cannon-Albright L; Lessnick SL; Sharma S; Capecchi MR; Randall RLCancer Control 2011[Jul]; 18 (3): 196-203BACKGROUND: Synovial sarcoma is a soft tissue malignancy with a predilection for adolescents and young adults. Despite recent improvements in the understanding of its character and etiology, few therapeutic advances have been made. The mortality rate is high among the young population it affects. The low incidence of most subtypes of sarcoma, such as synovial sarcoma, makes disease-specific trials difficult to organize. The biological differences between sarcoma subtypes make inclusion of multiple types in general trials unsatisfactory as well. METHODS: A review of the literature regarding targetable pathways in synovial sarcoma was undertaken. A strategy has been devised to utilize available technologies in order to prioritize drug trial planning. RESULTS: Cell culture and xenograft research with synovial sarcoma cell lines have identified some critical pathways that may be targetable. Promising therapeutic strategies include newer cytotoxic chemotherapies, antiangiogenic agents, anti-IGF1R pathway agents, anti-Bcl-2/proapoptotic agents, and histone deacetylase complex inhibitors. CONCLUSIONS: We propose to prioritize potential therapeutic strategies via preclinical testing of agents in a genetic mouse model of synovial sarcoma. Preclinical optimization of treatment regimens can guide the development of more focused patient trials.|Adolescent[MESH]|Angiogenesis Inhibitors/pharmacology/*therapeutic use[MESH]|Animals[MESH]|Antineoplastic Agents/pharmacology/*therapeutic use[MESH]|Cell Line, Tumor[MESH]|Child[MESH]|Disease Models, Animal[MESH]|Drug Evaluation, Preclinical[MESH]|Genetic Engineering[MESH]|Humans[MESH]|Mice[MESH]|Mice, Transgenic[MESH]|Molecular Targeted Therapy[MESH]|Sarcoma, Synovial/*drug therapy/mortality/pathology[MESH]|Xenograft Model Antitumor Assays[MESH]|Young Adult[MESH] |
